CN105940001B - 作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物 - Google Patents
作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物 Download PDFInfo
- Publication number
- CN105940001B CN105940001B CN201480073461.XA CN201480073461A CN105940001B CN 105940001 B CN105940001 B CN 105940001B CN 201480073461 A CN201480073461 A CN 201480073461A CN 105940001 B CN105940001 B CN 105940001B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- alkyl
- mmol
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(C*)CCNC Chemical compound CC(C)(C*)CCNC 0.000 description 11
- PKPFWNUHOQYQLE-UHFFFAOYSA-N CC(C)CN(CC1)CCC1c1cnc2[n](Cc(cc3)ccc3C(NO)=O)ccc2c1 Chemical compound CC(C)CN(CC1)CCC1c1cnc2[n](Cc(cc3)ccc3C(NO)=O)ccc2c1 PKPFWNUHOQYQLE-UHFFFAOYSA-N 0.000 description 1
- KLZGJQGBUIXLAH-UHFFFAOYSA-N CC(CC1)CCN1c1cnc2[n](Cc(cc3)ccc3C(OC)=O)ccc2c1 Chemical compound CC(CC1)CCN1c1cnc2[n](Cc(cc3)ccc3C(OC)=O)ccc2c1 KLZGJQGBUIXLAH-UHFFFAOYSA-N 0.000 description 1
- WACYTCDCBQXUAW-UHFFFAOYSA-N CC1(C)CN(C)CC1 Chemical compound CC1(C)CN(C)CC1 WACYTCDCBQXUAW-UHFFFAOYSA-N 0.000 description 1
- MRIHUWLLJIAGPK-UHFFFAOYSA-N CC1(CCC1)C(N(CC1)CCN1C(c1c(N)[n](Cc(cc2)ccc2C(OC)=O)c(C)c1)=C=CC)=O Chemical compound CC1(CCC1)C(N(CC1)CCN1C(c1c(N)[n](Cc(cc2)ccc2C(OC)=O)c(C)c1)=C=CC)=O MRIHUWLLJIAGPK-UHFFFAOYSA-N 0.000 description 1
- KBBUTNQCGLIJHF-UHFFFAOYSA-N CCC(CC)(CN(CC1)CCN1c1c(cc[n]2Cc(cc3)ccc3C(OC)=O)c2ncc1C)F Chemical compound CCC(CC)(CN(CC1)CCN1c1c(cc[n]2Cc(cc3)ccc3C(OC)=O)c2ncc1C)F KBBUTNQCGLIJHF-UHFFFAOYSA-N 0.000 description 1
- DMVPZPIURUFOCW-CYMBIFCZSA-N CCC/C=C(/C[n]1c2cc(Br)cnc2cc1)\C=C/CC(OC)=O Chemical compound CCC/C=C(/C[n]1c2cc(Br)cnc2cc1)\C=C/CC(OC)=O DMVPZPIURUFOCW-CYMBIFCZSA-N 0.000 description 1
- QTYNAYLADTZIOC-UHFFFAOYSA-N COC(C1=CCC(C[n](cc2)c3c2cc(C2CCN(Cc4ccncc4)CC2)cn3)C=C1)=O Chemical compound COC(C1=CCC(C[n](cc2)c3c2cc(C2CCN(Cc4ccncc4)CC2)cn3)C=C1)=O QTYNAYLADTZIOC-UHFFFAOYSA-N 0.000 description 1
- ZGFJDRJEMGHVMY-UHFFFAOYSA-N COC(c1ccc(CN(C=CC2=C3)C2=NCC=C3N2CCC3(CN(Cc4ccccn4)C3)CCC2)cc1)=C Chemical compound COC(c1ccc(CN(C=CC2=C3)C2=NCC=C3N2CCC3(CN(Cc4ccccn4)C3)CCC2)cc1)=C ZGFJDRJEMGHVMY-UHFFFAOYSA-N 0.000 description 1
- GIXHMDLDCOYCEI-UHFFFAOYSA-N COC(c1ccc(C[n](cc2)c3c2c(C2=CCN(Cc4cccc(F)c4)CC2)ccn3)cc1)O Chemical compound COC(c1ccc(C[n](cc2)c3c2c(C2=CCN(Cc4cccc(F)c4)CC2)ccn3)cc1)O GIXHMDLDCOYCEI-UHFFFAOYSA-N 0.000 description 1
- FLZMUZNKGDPNKN-UHFFFAOYSA-N COC(c1ccc(C[n](cc2)c3c2c(C2CCN(Cc4ccc(CN5CCOCC5)cc4)CC2)ccn3)cc1)=O Chemical compound COC(c1ccc(C[n](cc2)c3c2c(C2CCN(Cc4ccc(CN5CCOCC5)cc4)CC2)ccn3)cc1)=O FLZMUZNKGDPNKN-UHFFFAOYSA-N 0.000 description 1
- OCYZYCAZZUBHGR-UHFFFAOYSA-N COC(c1ccc(C[n]2c3ncc(C4CCN(Cc5n[o]c(C(F)(F)F)n5)CC4)cc3cc2)cc1)=O Chemical compound COC(c1ccc(C[n]2c3ncc(C4CCN(Cc5n[o]c(C(F)(F)F)n5)CC4)cc3cc2)cc1)=O OCYZYCAZZUBHGR-UHFFFAOYSA-N 0.000 description 1
- GDEJBUAUZNQQBK-UHFFFAOYSA-N COC(c1ccc(C[n]2c3nccc(C4C=CN(Cc5cccc(CN6CCOCC6)c5)CC4)c3cc2)cc1)=O Chemical compound COC(c1ccc(C[n]2c3nccc(C4C=CN(Cc5cccc(CN6CCOCC6)c5)CC4)c3cc2)cc1)=O GDEJBUAUZNQQBK-UHFFFAOYSA-N 0.000 description 1
- AUWKFATUSFQZRJ-UHFFFAOYSA-N COC(c1ccc(C[n]2ccc3c2ncc(-c(c(F)c2)ccc2F)c3)cc1)=O Chemical compound COC(c1ccc(C[n]2ccc3c2ncc(-c(c(F)c2)ccc2F)c3)cc1)=O AUWKFATUSFQZRJ-UHFFFAOYSA-N 0.000 description 1
- JAAFUBFWGARMBX-KDURUIRLSA-N C[C@H](C1)N(CC(C)(C)[O-])[C@@H](C)CN1c1ccnc2c1cc[n]2Cc(cc1)ccc1C(OC)=O Chemical compound C[C@H](C1)N(CC(C)(C)[O-])[C@@H](C)CN1c1ccnc2c1cc[n]2Cc(cc1)ccc1C(OC)=O JAAFUBFWGARMBX-KDURUIRLSA-N 0.000 description 1
- AOPGLVUYOSAHPI-UHFFFAOYSA-N ONC(c1ccc(C[n](cc2)c3c2c(C2CCN(Cc4ccc(CN5CCOCC5)cc4)CC2)ccn3)cc1)=O Chemical compound ONC(c1ccc(C[n](cc2)c3c2c(C2CCN(Cc4ccc(CN5CCOCC5)cc4)CC2)ccn3)cc1)=O AOPGLVUYOSAHPI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130154455 | 2013-12-12 | ||
| KR10-2013-0154455 | 2013-12-12 | ||
| PCT/IB2014/002768 WO2015087151A1 (en) | 2013-12-12 | 2014-12-12 | Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105940001A CN105940001A (zh) | 2016-09-14 |
| CN105940001B true CN105940001B (zh) | 2018-02-06 |
Family
ID=53370682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480073461.XA Expired - Fee Related CN105940001B (zh) | 2013-12-12 | 2014-12-12 | 作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9650379B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3080125B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2016540024A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101689394B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105940001B (cg-RX-API-DMAC7.html) |
| DK (1) | DK3080125T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2704704T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20181965T1 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3080125T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3080125T (cg-RX-API-DMAC7.html) |
| TR (1) | TR201900057T4 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015087151A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015157504A1 (en) | 2014-04-11 | 2015-10-15 | Taipei Medical University | Histone deacetylase inhibitors |
| NZ739211A (en) | 2015-07-27 | 2019-05-31 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| BR112017027798B1 (pt) | 2015-07-27 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| HRP20230052T1 (hr) | 2015-07-27 | 2023-03-03 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| HRP20220003T1 (hr) | 2015-08-04 | 2022-04-01 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| FI3362445T3 (fi) | 2015-10-12 | 2023-03-21 | Chong Kun Dang Pharmaceutical Corp | Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| IT201700041723A1 (it) | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| TW201920170A (zh) * | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| KR102236356B1 (ko) | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | 루푸스의 예방 또는 치료를 위한 조성물 |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| KR20200041812A (ko) * | 2018-10-12 | 2020-04-22 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 억제제 및 메토트렉세이트를 포함하는 약학적 조성물 |
| CN113874369B (zh) | 2019-05-31 | 2024-08-27 | 株式会社钟根堂 | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物 |
| CN115443329A (zh) | 2019-06-27 | 2022-12-06 | 乔治华盛顿大学国会特许非营利公司 | Hdac6激活的巨噬细胞、其组合物及用途 |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| TWI908740B (zh) * | 2019-10-09 | 2025-12-21 | 美商百歐克斯製藥公司 | 口服補體因子d抑制劑 |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
| CN115417877B (zh) * | 2022-09-20 | 2024-05-14 | 杭州师范大学 | 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013052110A1 (en) * | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2013062344A1 (en) * | 2011-10-28 | 2013-05-02 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
| WO2013078544A1 (en) * | 2011-11-29 | 2013-06-06 | Beta Pharma Canada Inc. | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE38506E1 (en) | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP2292593A3 (en) | 2000-09-29 | 2011-05-25 | TopoTarget UK Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| BRPI0817897A2 (pt) * | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| MX2010006243A (es) * | 2007-12-06 | 2010-08-31 | Schering Corp | Moduladores de gamma secretasa. |
| KR101168801B1 (ko) | 2009-03-27 | 2012-07-25 | 주식회사종근당 | 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 |
| JP5838157B2 (ja) | 2009-07-22 | 2015-12-24 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイThe Board Of Trustees Of The University Of Illinois | Hdac阻害剤およびそれを用いる治療法 |
| USRE47009E1 (en) * | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| WO2012178208A2 (en) * | 2011-06-24 | 2012-12-27 | The Trustees Of The Stevens Institute Of Technology | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
-
2014
- 2014-12-12 HR HRP20181965TT patent/HRP20181965T1/hr unknown
- 2014-12-12 CN CN201480073461.XA patent/CN105940001B/zh not_active Expired - Fee Related
- 2014-12-12 TR TR2019/00057T patent/TR201900057T4/tr unknown
- 2014-12-12 JP JP2016539198A patent/JP2016540024A/ja active Pending
- 2014-12-12 KR KR1020140179702A patent/KR101689394B1/ko not_active Expired - Fee Related
- 2014-12-12 PL PL14869323T patent/PL3080125T3/pl unknown
- 2014-12-12 PT PT14869323T patent/PT3080125T/pt unknown
- 2014-12-12 ES ES14869323T patent/ES2704704T3/es active Active
- 2014-12-12 US US15/103,597 patent/US9650379B2/en not_active Expired - Fee Related
- 2014-12-12 WO PCT/IB2014/002768 patent/WO2015087151A1/en not_active Ceased
- 2014-12-12 EP EP14869323.7A patent/EP3080125B1/en active Active
- 2014-12-12 DK DK14869323.7T patent/DK3080125T3/en active
-
2018
- 2018-04-12 JP JP2018076529A patent/JP6561167B2/ja not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013052110A1 (en) * | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2013062344A1 (en) * | 2011-10-28 | 2013-05-02 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
| WO2013078544A1 (en) * | 2011-11-29 | 2013-06-06 | Beta Pharma Canada Inc. | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150068923A (ko) | 2015-06-22 |
| ES2704704T3 (es) | 2019-03-19 |
| PT3080125T (pt) | 2018-12-14 |
| WO2015087151A1 (en) | 2015-06-18 |
| EP3080125A4 (en) | 2017-08-02 |
| JP2016540024A (ja) | 2016-12-22 |
| JP6561167B2 (ja) | 2019-08-14 |
| HRP20181965T1 (hr) | 2019-02-08 |
| KR101689394B1 (ko) | 2016-12-23 |
| PL3080125T3 (pl) | 2019-06-28 |
| TR201900057T4 (tr) | 2019-01-21 |
| DK3080125T3 (en) | 2019-01-07 |
| JP2018109068A (ja) | 2018-07-12 |
| EP3080125A1 (en) | 2016-10-19 |
| US9650379B2 (en) | 2017-05-16 |
| EP3080125B1 (en) | 2018-10-10 |
| CN105940001A (zh) | 2016-09-14 |
| US20160289230A1 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105940001A (zh) | 作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物 | |
| CN109641899B (zh) | 作为内体Toll样受体抑制剂的化合物及组合物 | |
| CN108440370B (zh) | 病毒复制抑制剂 | |
| CN105829309B (zh) | Gpr6的四氢吡啶并吡嗪调节剂 | |
| CN106414432B (zh) | 选择性取代的喹啉化合物 | |
| CN105358556B (zh) | 用于选择性组蛋白脱乙酰酶抑制剂的新型化合物以及包含其的药物组合物 | |
| CN103906732A (zh) | 用作hdac抑制剂的异羟肟酸酯衍生物以及包含所述衍生物的药物组合物 | |
| CN110088099A (zh) | 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法 | |
| WO2024051755A1 (zh) | Kif18a抑制剂化合物、药物组合物及其制备方法和应用 | |
| WO2014137719A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| CN105524068B (zh) | 氮杂双环衍生物、其制法与医药上的用途 | |
| CN117858877A (zh) | Enl/af9 yeats的c连接抑制剂 | |
| CN101878217A (zh) | 皮肤疾病的预防和/或治疗剂 | |
| CN115427035A (zh) | Enl/af9 yeats抑制剂 | |
| CN108137616B (zh) | 包含吡嗪并[2,3-b][1,4]噁嗪-3-酮或相关环系的抗菌剂 | |
| KR20240168922A (ko) | 방향족 헤테로사이클릭 화합물, 그의 제조 방법 및 그의 용도 | |
| HK1225018B (en) | Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same | |
| HK1225018A1 (en) | Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same | |
| TW201410677A (zh) | 縮環雜環化合物 | |
| HK40112157A (en) | The pharmaceutical use of enpp1 inhibitors | |
| HK40094991B (en) | Heterocyclic compound with antitumor activity and use thereof | |
| HK40094991A (en) | Heterocyclic compound with antitumor activity and use thereof | |
| WO2024199444A1 (zh) | 杂芳环化合物及其制备方法和用途 | |
| HK40082693B (en) | 8-oxo-3-azabicyclo[3.2.1]octane compounds or salts thereof, and preparation method and use thereof | |
| HK1260073B (en) | Viral replication inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1225018 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1225018 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180206 |